Hydroxyurea treatment for sickle cell anemia during pregnancy and lactation: Current evidence and knowledge gaps
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2023-05 · 43 (5) · 419-429
DOI: 10.1002/phar.2793 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, online erschienen am 26.03.2023. Verfasst von Min Dong und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA. Hauptthemen laut MEDLINE: Hydroxyurea, Anemia, Sickle Cell. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIH HHS, National Institutes of Health.
Themen: Stillen
Abstract (Originalsprache)
Sickle cell anemia (SCA) is a life‐threatening genetic condition contributing to high‐risk pregnancies affecting both the mother and fetus. With improved management of children with SCA, this life‐threatening hematological disorder has evolved into a chronic disease of adults, and consequently parenthood has now become a possible and important life goal for many patients. Providing continuous management with healthy red blood cell function and avoiding SCA‐associated complications, such as pain crises, acute chest syndrome, and stroke, are crucial for a healthy pregnancy. Despite its excellent safety profile in non‐pregnant adults and children, and based on theoretical concerns derived from data using animal models and supraphysiological dosing, hydroxyurea is currently contraindicated for pregnant and lactating women with SCA. Clinical experience of hydroxyurea use during pregnancy is increasingly reported, however, and has shown inconsistent results of fetal or infant adverse effects. How the hydroxyurea exposure level may correlate with pregnancy outcomes is still unclear. Accordingly, efforts should be made to systemically evaluate exposure and safety of hydroxyurea treatment during pregnancy and lactation. Novel approaches such as physiologically based pharmacokinetic (PBPK) modeling, coupled with the ex vivo human placental cotyledon perfusion assay, provide opportunities to understand hydroxyurea exposure not only in pregnant women but also in the developing fetus. Combined with animal data, research using these approaches might be able to define safe and effective hydroxyurea dosing regimens for pregnant and lactating women with SCA, when the benefits of continuing hydroxyurea treatment likely outweigh the risks of non‐treatment, by avoiding substantial morbidity and even mortality for both mothers and infants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
- Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
- Division of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
- Pharmacometrics/Modeling & Simulation, Research & Development, Pharmaceuticals, Bayer AG, Leverkusen, Germany.
ORCID-Profile: Min Dong
Förderung
- NIH HHS
- National Institutes of Health
Zitieren
APA
Dong, M., Ware, R. E., Dallmann, A., & Vinks, A. A. (2023). Hydroxyurea treatment for sickle cell anemia during pregnancy and lactation: Current evidence and knowledge gaps. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 43(5), 419-429. https://doi.org/10.1002/phar.2793
Vancouver
Dong M, Ware RE, Dallmann A, Vinks AA. Hydroxyurea treatment for sickle cell anemia during pregnancy and lactation: Current evidence and knowledge gaps. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2023;43(5):419-429. doi:10.1002/phar.2793
BibTeX
@article{Dong2023,
author = {Dong, Min and Ware, Russell E and Dallmann, André and Vinks, Alexander A},
title = {Hydroxyurea treatment for sickle cell anemia during pregnancy and lactation: Current evidence and knowledge gaps},
journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
year = {2023},
volume = {43},
number = {5},
pages = {419--429},
doi = {10.1002/phar.2793}
}
EUVIMED